Photo taken on Nov. 7, 2021 shows the booth of AstraZeneca at the Medical Equipment and Healthcare Products Exhibition Area of the 4th China International Import Expo (CIIE) in east China's Shanghai. (Xinhua/Zhang Yuwei)
BEIJING, Nov. 2 (Xinhua) -- AstraZeneca, a leading global pharmaceutical company, announced to unveil four new drugs for the first time at the upcoming fifth China International Import Expo (CIIE), which will be held in Shanghai from Nov. 5 to 10.
The four drugs to appear at the CIIE include a rare disease drug, Soliris, which is used to treat certain blood disorders and had recently received approval to be sold in China, and Evusheld, a long-acting antibody combination for the treatment of the COVID-19.
Another two are important innovative drugs for the treatment of tumor, Enhertu and Calquence. The former is used to treat adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, while the latter is for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL).
During the CIIE, AstraZenec will introduce its journey in China in terms of different treatment sectors, its high-quality innovative products, holistic disease management solutions, and its layout in rare diseaseand autoimmunity.
According to the drugmaker, it will explore new cooperation opportunities with partners from all fields to strengthen industrial innovation and will seek global opportunities based on China's industrial advancement.
(Edited by Li Shimeng with Xinhua Silk Road, lishimeng@xinhua.org)
A single purchase
